The DOI matches its Crossref record; 49 of the 54 references it cites were found in a registry or an index.
SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
Published version of a preprint
Abstract
Purpose: The CD38 cell surface antigen is expressed in diverse hematologic malignancies including multiple myeloma, B-cell non-Hodgkin lymphoma (NHL), B-cell chronic lymphocytic leukemia, B-cell acute lymphoblastic leukemia (ALL), and T-cell ALL. Here, we assessed the antitumor activity of the anti-CD38 antibody SAR650984. Experimental Design: Activity of SAR650984 was examined on lymphoma, leukemia and multiple myeloma cell lines, primary multiple myeloma samples, and multiple myeloma xenograft models in immunodeficient mice. Results: We identified a humanized anti-CD38 antibody with strong proapoptotic activity independent of cross-linking agents, and potent effector functions including complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antibody-dependent cellular phagocytosis (ADCP), equivalent in vitro to rituximab in CD20+ and CD38+ models. This unique antibody, termed SAR650984, inhibited the ADP-ribosyl cyclase activity of CD38, likely through an allosteric antagonism as suggested by 3D structure analysis of the complex. In vivo, SAR650984 was active in diverse NHL, ALL, and multiple myeloma CD38+ tumor xenograft models. SAR650984 demonstrated single-agent activity comparable with rituximab or cyclophosphamide in Daudi or SU-DHL-8 lymphoma xenograft models with induction of the proapoptotic marker cleaved capase-7. In addition, SAR650984 had more potent antitumor activity than bortezomib in NCI-H929 and Molp-8 multiple myeloma xenograft studies. Consistent with its mode of action, SAR650984 demonstrated potent proapoptotic activity against CD38+ human primary multiple myeloma cells. Conclusion: These results validate CD38 as a therapeutic target and support the current evaluation of this unique CD38-targeting functional antibody in phase I clinical trials in patients with CD38+ B-cell malignancies. Clin Cancer Res; 20(17); 4574–83. ©2014 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Isatuximab exerts its anti-tumor effects through various mechanisms, including ADCC, ADCP, and CDC [166].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [166]
Citations
Cites
Damle, R. N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S. L., Buchbinder, A., Budman, D. R., Dittmar, K., Kolitz, J. E., et al. (1999) · Blood · doi:10.1182/blood.v94.6.1840 · Cited by 2,634
Reinherz, E. L., Kung, P. C., Goldstein, G., Levey, R. H., & Schlossman, S. F. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1588 · Cited by 1,629
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J. B., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,172
de Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C. A., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 983
Terstappen, L. W. M. M., Huang, S., Safford, M., Lansdorp, P., & Loken, M. R. (1991) · Blood · doi:10.1182/blood.v77.6.1218.1218 · Cited by 845
Hamblin, T. J., Orchard, J. A., Ibbotson, R. E., Davis, Z. A., Thomas, P., Stevenson, F. K., & Oscier, D. G. (2002) · Blood · doi:10.1182/blood.v99.3.1023 · Cited by 618
Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple Myeloma
Lin, P. Y., Owens, R., Tricot, G. J. K., & Wilson, C. S. (2004) · American Journal of Clinical Pathology · doi:10.1309/74r4tb90buwh27jx · Cited by 454
CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia
Ibrahim, S., Keating, M. J., Do, K.-A., O'Brien, S. M., Huh, Y. O., Jilani, I. B., Lerner, S. A., Kantarjian, H. M., & Albitar, M. X. (2001) · Blood · doi:10.1182/blood.v98.1.181 · Cited by 451
CD38 and CD157: A long journey from activation markers to multifunctional molecules
Quarona, V., Zaccarello, G., Chillemi, A., Brunetti, E., Singh, V. K., Ferrero, E., Funaro, A., Horenstein, A. L., & Malavasi, F. (2013) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21092 · Cited by 269
Cited by
Sorted by citations
Items 301–324 of 324
Isatuximab: Nursing Considerations for Use in the Treatment of Multiple Myeloma
Wilmoth, J., Colson, K., Dubin, F., & Kellam, C. (2021) · Clinical journal of oncology nursing · doi:10.1188/21.cjon.706-712
Radionuclide Therapy of Leukemias and Multiple Myeloma
Sollini, M., Bartoli, F., Galimberti, S., Boni, R., & Erba, P. A. (2022) · Springer eBooks · doi:10.1007/978-3-319-26067-9_48-2
Antibody Therapies for Multiple Myeloma
Kanellias, N., Gavriatopoulou, M., & Terpos, E. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98656
Hosokawa, M., Nagamine, K., Aochi, H., Nakayama, K., Sakuragi, M., Morikawa, T., Nakao, M., Kiyokawa, T., Kato, H., Tomiyama, Y., et al. (2022) · Japanese Journal of Transfusion and Cell Therapy · doi:10.3925/jjtc.68.412
Campbell, R. B., Tran, C., Park, E., & Flores, P. L. R. (2022) · Current Drug Therapy · doi:10.2174/1574885517666220426092902 · Cited by 1
Research progress in the role of CD38 in clinical tumor treatment.
He, Z., Liu, X., & Zhou, Y. (2022) · PubMed Central · doi:10.11817/j.issn.1672-7347.2022.210351
Kläsener, K., Herrmann, N., Håversen, L., Sundell, T., Sundqvist, M., Lundqvist, C., Manna, P. T., Jonsson, C. A., Visentini, M., Sass, D. L., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3872713/v1
Myklebust, E. M., Schjesvold, F. H., Frigessi, A., Leder, K., Foo, J., & Köhn‐Luque, A. (2024) · medRxiv · doi:10.1101/2024.05.02.24306607
Jiang, H., Acharya, C., An, G. C., Zhong, M., Feng, X., Wang, L., Dasilva, N., Song, Z., Yang, G., Adrian, F., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02443-z
RetractedClinical Progress of CAR-T Cell Therapy for Refractory/Relapsed Acute T Lymphoblastic Leukemia
梁, 明. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.153664
First experience with Isatuximab in newly diagnosed multiple myeloma patients. Case report
Semenova, A., Zemlyakov, N., Kamyshanov, S. S., Cherentsova, A. I., Субботин, А. С., Tumyan, G. S., Baranova, O. Y., Строганова, А. М., & Arakelyan, A. V. (2026) · Journal of Modern Oncology · doi:10.26442/18151434.2025.4.203551
Mechanism of action of isatuximab in multiple myeloma. Literature review and clinical observation
Soloveva, M. V., Solovev, M. V., & Mendeleeva, L. P. (2026) · Oncohematology · doi:10.17650/1818-8346-2026-21-1-59-65
Inoue, Y., Harada, T., Oda, A., Ohara, N., Nakagawa, H., Urushihara, M., Nakao, T., & Matsuoka, K.-I. (2026) · International Journal of Hematology · doi:10.1007/s12185-026-04210-5
Liu, Y., Mo, C. C., Midha, S., Hartley-Brown, M. A., Lee, H. C., Franz, J. K., Nadeem, O., Nicholson, T., Salman, T. J., Fortune, A., et al. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2660911
Structural dissection of CD38 antigen engagement by CAR binders and rational affinity tuning
Cheng, Z., Zhang, L. Q., Liang, Z., Huang, Q., Tang, Z., Shi, X., Liu, L., Yang, G., & Yan, L. (2026) · iScience · doi:10.1016/j.isci.2026.115937
Eiring, P., Doose, S., Bauer, N., & Sauer, M. (2026) · BIO-PROTOCOL · doi:10.21769/bioprotoc.5767
Uyemura, B. S., & Callander, N. S. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.07.014
Therapeutic biologics interference in serological and pre-transfusion testing
Trummer, P., Habicht, C. P., Scharberg, E. A., & Schneeweiß, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1888597
Yu, L., Li, C., Guo, D., & Cui, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1932951
Risch, H., Gebhardt, A. J., Hagen, N., Duttmann, A., Dannenberg, M., Kämereit, S., Ahrens, R., Al-Bazaz, M., Riecken, K., Fehse, B., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1915205
Kanbay, M., Çöpür, S., Gulmaliyev, I., Süsal, C., Süsal, C., Covic, A., & Altındal, M. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag238
Metadata
- Authors
- Deckert, J., Wetzel, M.-C., Bartle, L. M., Skaletskaya, A., Goldmacher, V. S., Vallée, F., Zhou-Liu, Q., Ferrari, P., Pouzieux, S., Lahoute, C., Dumontet, C., Plesa, A., Chiron, M., Lejeune, P., Chittenden, T., Park, P. U., & Blanc, V.
- Affiliations
- ImmunoGen (United States) (US)
- Sanofi (France) (FR)
- Centre National de la Recherche Scientifique (FR)
- 5Hematology Laboratory, Hospices Civils de Lyon, Pierre Bénite, France and CRCL, INSERM 1052-CNRS 5286, Lyon, France.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2014-09-01
- Volume
- 20
- Issue
- 17
- Pages
- 4574-4583
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2072259475
- Cited by
- 333
- References
- 54
- Citations by year
- 2026: 17 · 2025: 23 · 2024: 22 · 2023: 25 · 2022: 48 · 2021: 48 · 2020: 36 · 2019: 25 · 2018: 22 · 2017: 20 · 2016: 24 · 2015: 21 · 2014: 2
- FWCI
- 15.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- anti-CD38 monoclonal antibody, CD38, multiple myeloma, B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, allosteric antagonism, complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, rituximab, xenograft models, apoptosis
- MeSH terms
- Rituximab, Animals, Antibodies, Monoclonal, Antibody-Dependent Cell Cytotoxicity, Humans, Membrane Glycoproteins, Multiple Myeloma, Lymphoma, B-Cell, Hematologic Neoplasms, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, ADP-ribosyl Cyclase 1, Antibodies, Monoclonal, Murine-Derived, Antibodies, Monoclonal, Humanized, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
